# The Incidence of Extra-Articular Manifestations in Participants With Ankylosing Spondylitis Treated With Golimumab (MK-8259-012)

> **NCT01668004** · PHASE4 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 101 (actual)

## Conditions studied

- Ankylosing Spondylitis

## Interventions

- **BIOLOGICAL:** Golimumab

## Key facts

- **NCT ID:** NCT01668004
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-09-03
- **Primary completion:** 2015-04-30
- **Final completion:** 2015-04-30
- **Target enrollment:** 101 (ACTUAL)
- **Last updated:** 2019-02-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01668004

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01668004, "The Incidence of Extra-Articular Manifestations in Participants With Ankylosing Spondylitis Treated With Golimumab (MK-8259-012)". Retrieved via MORVS 2026-11-03 from https://api.morvs.ai/clinical/NCT01668004. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*